Stocks of Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) traded higher last session on Wall Street, up 3.14% to $333.39.
MDGL stock price is now 6.79% away from the 50-day moving average and 28.22% away from the 200-day moving average. The market capitalization of the company currently stands at $7.27B.
On June 11, 2024, Wolfe Research recently initiated its ‘Outperform’ rating on the stock quoting a target price of $382, while ‘BofA Securities’ rates the stock as ‘Underperform’
In other news, CRAVES FRED B, Director sold 3,600 shares of the company’s stock on Dec 03 ’24. The stock was sold for $1,135,122 at an average price of $315.31. Upon completion of the transaction, the Director now directly owns 11,000 shares in the company, valued at $3.67 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Nov 25 ’24, Director CRAVES FRED B sold 3,400 shares of the business’s stock. A total of $1,191,028 was realized by selling the stock at an average price of $350.30. This leaves the insider owning 14,600 shares of the company worth $4.87 million. A total of 15.70% of the company’s stock is owned by insiders.
During the past 12 months, Madrigal Pharmaceuticals Inc has had a low of $168.25 and a high of $368.29. As of last week, the company has a debt-to-equity ratio of 0.15, a current ratio of 5.98, and a quick ratio of 5.93. The fifty day moving average price for MDGL is $312.205 and a two-hundred day moving average price translates $260.0137 for the stock.
The latest earnings results from Madrigal Pharmaceuticals Inc (NASDAQ: MDGL) was released for 2024-09-30. The net profit margin was -675.24% and return on equity was -129.76% for MDGL.
